Literature DB >> 616060

Effect of sites of blood sampling in determination of the galactose elimination capacity.

N Tygstrup.   

Abstract

The galactose elimination capacity was calculated from both arterial and capillary or peripheral venous curves in twenty patients. The capillary curves on the average were delayed 1.4 min in relation to the arterial curves. No significant difference was found between the calculated galactose elimination capacity from either curve. On the average the slope of the venous curves was smaller than that of the arterial curve, and their time delay was very variable (from 1.55 to 5.27 min). Galactose elimination capacity calculated from venous curves was smaller than those calculated from arterial curves, especially in patients with a high galactose elimination capacity. Capillary blood sampling may replace arterial puncture for routine use, whereas venous blood sampling introduces a significant bias.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 616060     DOI: 10.3109/00365517709092638

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  10 in total

1.  Age-dependency of galactose elimination capacity in healthy children and children with chronic liver disease.

Authors:  Aksel Lange; Henning Grønbæk; Hendrik Vilstrup; Susanne Keiding
Journal:  Scand J Gastroenterol       Date:  2010-11-01       Impact factor: 2.423

2.  Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper Sandager Mikkelsen; Kim Frisch; Ludvik Bass; Bo Martin Bibby; Susanne Keiding
Journal:  J Nucl Med       Date:  2011-08-29       Impact factor: 10.057

3.  Determination of hepatic galactose elimination capacity using 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model.

Authors:  Michael Sørensen
Journal:  Scand J Gastroenterol       Date:  2010-08-09       Impact factor: 2.423

Review 4.  Quantitative PET of liver functions.

Authors:  Susanne Keiding; Michael Sørensen; Kim Frisch; Lars C Gormsen; Ole Lajord Munk
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

5.  The galactose elimination capacity and mortality in 781 Danish patients with newly-diagnosed liver cirrhosis: a cohort study.

Authors:  Peter Jepsen; Hendrik Vilstrup; Peter Ott; Susanne Keiding; Per K Andersen; Niels Tygstrup
Journal:  BMC Gastroenterol       Date:  2009-06-30       Impact factor: 3.067

6.  Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.

Authors:  Michael Sørensen; Kasper S Mikkelsen; Kim Frisch; Gerda E Villadsen; Susanne Keiding
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

7.  Hepatic ethanol elimination kinetics in patients with cirrhosis.

Authors:  Gitte Dam; Michael Sørensen; Ole Lajord Munk; Susanne Keiding
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

8.  Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography.

Authors:  Michael Sørensen; Ole Lajord Munk; Frank Viborg Mortensen; Aage Kristian Olsen; Dirk Bender; Ludvik Bass; Susanne Keiding
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-15       Impact factor: 4.052

9.  Epigenetic and SP1-mediated regulation is involved in the repression of galactokinase 1 gene in the liver of neonatal piglets born to betaine-supplemented sows.

Authors:  Demin Cai; Mengjie Yuan; Haoyu Liu; Zhengqiang Han; Shifeng Pan; Yang Yang; Ruqian Zhao
Journal:  Eur J Nutr       Date:  2016-06-01       Impact factor: 5.614

10.  Pharmacokinetics of paroxetine in patients with cirrhosis.

Authors:  K Dalhoff; T P Almdal; K Bjerrum; S Keiding; H Mengel; J Lund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.